Gd-DTPA in clinical MR of the brain: 2. Extraaxial lesions and normal structures

Fifteen patients with suspected extraaxial tumors were evaluated with MR before and after intravenous injection of Gadolinium-DTPA (Gd-DTPA). Meningiomas (7), neurinomas (4), chordomas (2), a previously irradiated dural metastasis, and a giant aneurysm were studied. All the lesions except the dural metastasis enhanced. In two patients with asymptomatic meningiomas, the use of Gd-DTPA with MR allowed definitive diagnosis of the lesions when the routine MR did not. Gd-DTPA also provided improved definition of intracranial tumor margins, produced differential enhancement of dura and nasopharyngeal mucosa from tumor, and caused enhancement of the choroid plexus, some venous structures, the pituitary gland, and its stalk. The enhancement of the pituitary suggests a role for Gd-DTPA in the diagnosis of microadenomas. Routine T2-weighted images without Gd-DTPA were useful in differentiating neurinomas from meningiomas. Judicious use of Gd-DTPA should improve the ability of MR to detect extraaxial lesions, delineate their extent, and characterize their perfusion.     

Intraaxial brain masses: MR imaging-based diagnostic strategy--initial experience

PURPOSE: To develop and retrospectively determine the accuracy of a magnetic resonance (MR) imaging strategy to differentiate intraaxial brain masses, with histologic findings or clinical diagnosis as the reference standard. MATERIALS AND METHODS: The study was HIPAA compliant and was approved by the institutional review board. A waiver of informed consent was obtained. A strategy was developed on the basis of conventional MR imaging, diffusion-weighted MR imaging, perfusion MR imaging, and proton MR spectroscopy to classify intraaxial masses as low-grade primary neoplasms, high-grade primary neoplasms, metastatic neoplasms, abscesses, lymphomas, tumefactive demyelinating lesions (TDLs), or encephalitis. The strategy was evaluated by using data from 111 patients (46 women, 65 men; mean age, 48.9 years) with imaging results available on a departmental picture archiving and communication system from a 5-year search period. Bayesian statistics of the strategy elements and three clinical tasks were calculated. RESULTS: Search results identified 44 patients with high-grade and 14 with low-grade primary neoplasms, 24 with abscesses, 12 with lymphoma, 11 with TDLs, five with metastases, and one with encephalitis who had undergone conventional and advanced MR imaging. However, only 40 patients (25 women, 15 men; mean age, 45 years) had undergone all studies and had data to allow completion of the entire strategy. Accuracy, sensitivity, and specificity of the strategy, respectively, were 90%, 97%, and 67% for discrimination of neoplastic from nonneoplastic diseases, 90%, 88%, and 100% for discrimination of high-grade from low-grade neoplasms, and 85%, 84%, and 87% for discrimination of high-grade neoplasms and lymphoma from low-grade neoplasms and nonneoplastic diseases. CONCLUSION: An integrated MR imaging-based strategy, which is accurate in differentiation of several intraaxial brain masses, was proposed.     

MR Gd-DTPA enhancement of radiation brain injury.

MR examinations of 104 patients who had undergone radiotherapy to the brain were reviewed. Thirty-six patients received Gd-DTPA enhanced study during the course of MR evaluation and six of the patients showed enhancing radiation necrosis. Histopathological confirmations were obtained in three patients. Gd-DTPA enhancing radiation lesions were multiple and patchy in three patients, multiple and patchy with cyst formation in two and ring shaped in one. In terms of their distribution, enhancing lesions in four patients were seen only in the white matter within the irradiated field and these patients had undergone radiotherapy within five years. The interval after radiotherapy was more than eight years in two patients and their enhanced lesions were observed in both the white and gray matter. Histopathological findings of Gd-DTPA enhancing radiation necrosis were gliosis and coalescing vacuoles of the neural tissue. None of these enhanced radiation lesions showed significant mass effects. Patterns of the enhancement were not specific. It was considered to be difficult to differentiate tumor recurrence from radiation necrosis with conventional Gd-DTPA enhanced MR examinations. In one patient, delayed MR images after Gd-DTPA administration showed increases in the size and number of radiation enhanced lesions. Dynamic and delayed MR study might add more information to conventional imaging after Gd-DTPA. Further studies are necessary to differentiate radiation lesions from tumor recurrences.     

MR contrast enhancement of intracranial lesions with Gd-DTPA

Gd-DTPA is a paramagnetic contrast agent for MR that produces enhancement of lesions on T1-weighted images. Since it does not cross the intact blood-brain barrier (BBB), Gd-DTPA enhances only those pathologic processes that are associated with breakdown of the BBB and structures or lesions that are devoid of a BBB. Gd-DTPA improves conspicuity, helps characterize and delineate the extent of lesions, and increases the sensitivity for detection of cerebral abnormalities.     

MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA

The enhancement properties of gadolinium diethylenetriaminepentaacetic acid (DTPA) and gadolinium tetraazacyclododecanetetraacetic acid (DOTA) were compared using a rat glioma model. In vitro analysis included the calculation of T1 relaxivity and determination of characteristic curves. Enhancement of the intracerebral glioma was studied in 23 rats approximately 2 weeks after glioma implantation with Gd-DTPA in 12 rats and Gd-DOTA in 11 rats. Six rats were also studied 1 week after implantation. Gd-DTPA exhibited a slightly greater T1 relaxivity in vitro than Gd-DOTA. Enhancement of the glioma was also greater with Gd-DTPA than with Gd-DOTA (P less than .05).     

Dynamic MR imaging of the liver with Gd-DTPA: initial clinical results

Gd-DTPA was evaluated as a hepatic contrast agent for MR imaging. Twenty-six consecutive patients referred for suspected masses in the liver were studied at 1.5 T. Fourteen patients had hepatic metastases and one patient each had cholangiocarcinoma and multicentric hepatocellular carcinoma. Four patients had cavernous hemangiomas and the remainder had other benign lesions. Diagnoses were proved by biopsy, sonography, or radionuclide scintigraphy in 23 cases and by autopsy in one case. Precontrast scans were obtained by using standard pulse sequences. In addition, breath-hold scans were obtained before and after bolus administration of 0.1 mmol/kg Gd-DTPA by using a multislice T1-weighted gradient-echo pulse sequence with an ultrashort echo time. Mean lesion-liver signal difference/noise increased by 50% (p less than .01) in the immediate postcontrast phase. In two of 26 cases, multiple additional lesions as small as 3 mm were detected after contrast administration that were not seen before contrast administration. In no case was lesion-liver contrast worsened on scans obtained immediately after administration of contrast material. However, on delayed scans, detection of lesions worsened in some cases because of equilibration of contrast material between liver and lesion. These initial clinical results suggest that enhancement with Gd-DTPA is a practical method for improving lesion-liver contrast and has the potential to improve the accuracy of MR imaging in the liver. However, optimized fast imaging techniques are required for best results.     

Gd-DTPA administered MR imaging of intracranial mass lesions: a comparison with CT and precontrast MR

Magnetic resonance (MR) images of 13 intracranial mass lesions taken with the intravenous administration of gadolinium-DTPA were evaluated in comparison with precontrast computed tomography (CT), postcontrast CT, and precontrast MR. In the MR images taken with Gd-DTPA, tumor delineation improved in eight of 13 cases (62%) in comparison with precontrast MR images, and in seven of 13 cases (54%) in comparison with the overall evaluation of precontrast CT, postcontrast CT, and precontrast MR images. Tumor demarcation was unchanged in the remaining cases; no deterioration was observed with Gd-DTPA administration. MR imaging with Gd-DTPA should be performed to better evaluate the extent of intracranial mass lesions and to provide additional information.     

3D MR imaging with Gd-DTPA in head and neck lesions

Three-dimensional MR imaging technique is not a new concept, however, there is very little experience concerning clinical trials. Especially in head and neck lesions, the accuracu of this new imaging method has not yet been tested. A pilot study was performed to evaluate the diagnostic value of demonstrating the head and neck lesions and topographical structures implemented in a three-dimensional reconstruction of the entire head. The 3D reconstruction mode is based on the ray-tracting model. The application of the contrast medium Gd-DTPA proved to be helpful. Three-dimensional reconstruction revealed clear topographic details of the lesions, including the spread of infiltration and destruction of soft tissue. Additionally, the simultaneous view of multiple slices in different orientations is an ideal method for evalauting the spread of the lesion and to visualize the relation between lesion and surrounding tissue. Offprint request to: T. Vogl     

MR in phenylketonuria-related brain lesions

PURPOSE: Phenylketonuria (PKU) patients were examined by different MR techniques to explain the pathological changes observed in periventricular white brain matter using conventional MR imaging. MATERIAL AND METHODS: Fifteen patients with treated classical PKU were examined by 1H spectroscopy, relaxometry and diffusion imaging on a whole-body 1.5-T MR imager. RESULTS: Known PKU lesions characterized by T2 enhancement in periventricular white matter were observed in all patients. The MR spectra from the lesioned areas showed a significant decrease in choline concentration. The mean ADC of water decreased and tortuosity increased in PKU lesions compared to control data. CONCLUSION: The results support the following hypothesis: The T2 increase in the PKU lesion reflects a raised concentration of free water molecules (about 15%) that have an increased trajectory between collisions compared to the same region in controls. The increase in water mobility might be explained by changes in extracellular space volume and myelin sheaths, which, presumably, have a different geometry with more hydrophobic sites in PKU patients. The changes result in increased tortuosity and may be confirmed by the loss of anisotropy in PKU lesions.     

Clinical experience with routine Gd-DTPA administration for MR imaging of the brain

A retrospective analysis of intracranial magnetic resonance (MR scans of 514 patients who underwent nonselective Gd-DTPA enhanced MR imaging was performed to determine the efficacy of this protocol for Gd-DTPA administration. This report reviews the frequency and clinical significance of abnormally enhancing areas that were entirely undetectable on precontrast images or would have been missed without the retrospective knowledge of enhancement. Fifty-seven patients (11% of the 514 patients studied) showed enhancing lesions, with 16 (3.1% of the total) of these patients demonstrating one or more lesions identifiable only on postcontrast images. Of those 16 patients, 8 had other focal abnormalities on precontrast studies, whereas the remaining 8 (1.6% of the total) had negative precontrast studies. The new diagnoses affected clinical management directly in five patients and in another nine contributed potentially significant information. Considerations regarding a selective versus nonselective protocol for Gd-DTPA administration for intracranial MR imaging and the use of clinical information to augment these protocols are discussed.     

Intraventricular mass lesions of the brain: CT and MR findings.

One tenth of all CNS neoplasms involve the ventricles of the brain. These mass lesions are located in areas that are difficult to reach surgically, and because they are intraventricular, spread via the CSF is common. CT and MR imaging have been useful in demonstrating these masses, but imaging characteristics are usually nonspecific. The location of the mass and the patient's age provide the most helpful information in the differential diagnosis.     

Quantitative determination of Gd-DTPA concentration in T1-weighted MR renography studies.

A method for calculating contrast agent concentration from MR signal intensity (SI) was developed and validated for T(1)-weighted MR renography (MRR) studies. This method is based on reference measurements of SI and relaxation time T(1) in a Gd-DTPA-doped water phantom. The same form of SI vs. T(1) dependence was observed in human tissues. Contrast concentrations calculated by the proposed method showed no bias between 0 and 1 mM, and agreed better with the reference values derived from direct T(1) measurements than the concentrations calculated using the relative signal method. Phantom-based conversion was used to determine the contrast concentrations in kidney tissues of nine patients who underwent dynamic Gd-DTPA-enhanced 3D MRR at 1.5T and (99m)Tc-DTPA radionuclide renography (RR). The concentrations of both contrast agents were found to be close in magnitude and showed similar uptake and washout behavior. As shown by Monte Carlo simulations, errors in concentration due to SI noise were below 10% for SNR = 20, while a 10% error in precontrast T(1) values resulted in a 12-17% error for concentrations between 0.1 and 1 mM. The proposed method is expected to be particularly useful for assessing regions with highly concentrated contrast.     

Optimal dose of Gd-DTPA in dynamic MR studies.

The relationship between the administered dose d of Gd-DTPA and the accuracy of measurements of the glomerular filtration rate G and the cardiac output O was investigated. For a wide range of values the concentration of Gd-DTPA can be uniquely derived from MR signals and precontrast longitudinal relaxation time. Fixed and random errors in these measured variables were analyzed. Depending on noise level and the level of renal function, errors in G reach a minimum for d = 1.4-2.8 mmol. Random errors in G are relatively insensitive to d as long as d > 1.5 mmol. These results establish the feasibility of dynamic MR measurements using doses of Gd-DTPA that are several times lower than current standards.     

Acoustic neuromas: Gd-DTPA enhancement in MR imaging

Magnetic resonance (MR) imaging examinations were performed in ten patients with 12 acoustic neuromas before and after intravenous administration of 0.1 mmol/kg body weight gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA). The degree of enhancement was greatest with the inversion recovery sequence 1,500/500/44 (repetition time [TR]/inversion time/echo delay time [TE]), followed by spin-echo (SE) 544/44 (TR/TE) sequences, then by SE 1,500/44 and SE 1,500/80 sequences. After enhancement there was a 50% reduction for measured T1 values, 33% for T2, and no significant change for proton density. There were no toxic effects on patients. Enhanced CT scans failed to demonstrate lesions in six of 12 cases. Air-CT technique improved sensitivity in four of five cases. Enhanced MR imaging added significant clinical information in two small intracanalicular tumors and in one recurrent tumor.     

Trigeminal neuropathy: Gd-DTPA enhanced MR imaging

A review of 17 patients with Gd-DTPA enhancing lesions of the trigeminal nerve (6 patients with benign tumors, 4 with inflammatory disease, 7 with malignant tumors) was conducted to determine if contrast enhanced MR imaging is superior to nonenhanced imaging and to identify imaging characteristics that aid in separating benign and malignant disease. Contrast enhanced imaging appears to be superior to nonenhanced imaging in patients with intrinsic fifth nerve lesions. Malignant lesions are suggested by enlarged, enhancing fifth nerves with irregular margins and benign lesions by minimal or no enlargement with smooth margins. Overlap of imaging findings between benign and malignant disease strongly suggests that follow-up imaging and clinical findings are of utmost importance. Gadolinium-enhanced MR imaging of the fifth nerve is recommended in patients with trigeminal sensory or motor deficits as well as those with atypical trigeminal neuralgia.     

Erdheim-Chester disease: MR of intraaxial and extraaxial brain stem lesions.

A case of Erdheim-Chester disease demonstrates cerebral hemispheric involvement, as well as and intraaxial and extraaxial brain stem involvement in a patient with symptoms of paraparesis, urinary incontinence, visual loss, ataxia, vertigo, proptosis, and nystagmus. Persistent gadopentetate dimeglumine enhancement was noted in the extraaxial cervicomedullary brain stem lesion 23 days after injection. However, the supratentorial lesions fail to show similar persistent enhancement. This case also demonstrates MR features characteristic of retrobulbar infiltration.     

1H T1 and T2 measurements of the MR imaging contrast agents Gd-DTPA and Gd-DTPA BMA at 1.5T

We report in vitro T₁ and T₂ relaxation studies for the open-chain complexes Gd-DTPA and Gd-DTPA BMA. Measurements were performed on phantoms containing aqueous and plasma solutions of different concentrations by MR imaging in a 1.5T superconducting whole-body scanner. Longitudinal relaxation times T₁ were evaluated from serial turbo-FLASH experiments for concentrations less than 1 mM, whereas for larger concentrations the values were obtained from a standard inversion recovery (IR) sequence. Transverse relaxation times T₂ were determined using multi-echo spin-echo MRI protocols. The T₁ and T₂ relaxivities of the nonionic Gd-DTPA BMA are similar to those of the Gd-DTPA. The temperature dependencies of the relaxivities were determined over a temperature interval ranging from 21 to 50 °C and were found to be slightly different for the two contrast agents. In the case of Gd-DTPA BMA a larger deviation of the expected temperature behavior of the relaxivities was observed as compared with Gd-DTPA. Deviations from a strictly linear dependence of relaxation times on temperature were found at lower concentrations in aqueous solutions. In plasma solutions a high T₁/T₂ ratio was observed for low concentrations, which decreased monotonically with increasing concentrations. Received 2 October 1995; Revision received 17 April 1996; Accepted 24 April 1996     

MR imaging of the gastrointestinal tract: value of Gd-DTPA

To determine the value of gadolinium-DTPA (Gd-DTPA) as an MR contrast material for the gastrointestinal tract, we obtained T1-, T2-, and proton-density-weighted MR scans of the abdomen in 20 volunteers before and after oral administration of the compound (10 ml/kg of a 0.5- or 1.0-mM solution). Gd-DTPA was given either alone or with mannitol (15 or 30 g/l). Opacification of the small bowel after the administration of 1.0 mM Gd-DTPA was superior to that achieved after administration of the 0.5-mM solution. In the absence of Gd-DTPA, the pancreas could be delineated partly in 11 cases. After administration of Gd-DTPA, the pancreas could be well differentiated from stomach and duodenum in 16 of 20 cases. In the absence of mannitol, two of the five subjects had homogeneous opacification of the entire small bowel. When Gd-DTPA was given with either 15 or 30 g mannitol/l, homogeneous opacification of the entire small bowel was obtained in nine of 10 volunteers. Diarrhea not discomforting to the volunteers was noted in four of 20 cases. No abnormal blood tests were recorded after administration of Gd-DTPA. The results suggest that oral administration of Gd-DTPA (1.0 mM) given with mannitol (15 g/l) is effective as an MR contrast agent for the gastrointestinal tract. The formulation was found to be safe in a small series of 20 volunteers.